Post Profile






Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant

Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.
read more

share
See more about: American Society

Related Posts


Stem Cell Transplant Survivors May Be At Increased Risk Of Developing Heart Disease

Health : Medical News Today

New research appearing online in Blood, the Journal of the American Society of Hematology (ASH), suggests that long-term survivors of hematopoietic cell transplants (HCT) are at an increased risk of developing heart disease risk fac...

Promising New Stem Cell Research, Transplant Strategies

Health : Medical News Today

Studies of stem cell biology and transplant approaches presented at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patient...

Immunotherapy Strategy Could Be Beneficial for Relapsed Acute Myeloid Leukemia, Preliminary Data Show

Health : Newswise Medical News

Researchers present their preliminary results from the ongoing phase II trial of chemotherapy and pembrolizumab in relapsed or refractory acute myeloid leukemia at the 59th American Society of Hematology Annual Meeting in Atlanta on...

Cancer drug ibrutinib found helpful in treating graft versus host disease after transplant

Health : EurekAlert: Health

(American Society of Hematology) A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego shows patients who experience graft-versus-host disease ...

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

Diseases & Conditions / Cancer : EurekAlert: Cancer

(Seattle Children's) Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated...

Comments


Copyright © 2016 Regator, LLC